Curated News
By: NewsRamp Editorial Staff
April 16, 2026
Helus Pharma Appoints Neuroscience Veteran to Advance Mental Health Treatments
TLDR
- Helus Pharma appoints Dr. Ken Kramer, a neuroscience expert with 20+ years at top firms, to strengthen its pipeline and stakeholder engagement for a competitive edge in mental health treatments.
- Helus Pharma appointed Dr. Ken Kramer as senior vice president of medical affairs to advance its pipeline of novel serotonergic agonists through clinical development and scientific collaboration.
- Helus Pharma's focus on developing novel treatments for depression and anxiety aims to improve mental health care and provide durable relief for those suffering from these conditions.
- Helus Pharma's HLP003 has Breakthrough Therapy Designation for major depressive disorder, showcasing innovative approaches to mental health treatment through novel serotonergic agonists.
Impact - Why it Matters
This appointment represents a strategic move in the rapidly evolving mental health pharmaceutical landscape, where innovative treatments for depression and anxiety are urgently needed. With mental health conditions affecting millions globally and existing treatments often having limitations in efficacy or side effects, Helus Pharma's focus on novel serotonergic agonists could potentially offer new therapeutic options. Dr. Kramer's extensive experience at major pharmaceutical companies brings valuable expertise to advance clinical development and regulatory strategy, potentially accelerating the availability of new treatments. For patients struggling with treatment-resistant depression or anxiety, this development signals progress toward more effective medications that could improve quality of life and treatment outcomes.
Summary
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) under the commercial name of Cybin Inc., has announced a significant leadership appointment that signals its commitment to advancing mental health treatments. The company has named Dr. Ken Kramer, PhD, as senior vice president of medical affairs, bringing over two decades of neuroscience-focused medical affairs expertise from prominent organizations including Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. This strategic hire is expected to strengthen Helus Pharma's engagement with clinical and scientific stakeholders while supporting the advancement of its pipeline of proprietary NSAs designed to activate serotonin pathways and promote neuroplasticity.
Helus Pharma is currently developing two key investigational drugs: HLP003, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is in Phase 3 clinical development for adjunctive treatment of major depressive disorder, and HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. The company operates across Canada, the United States, the United Kingdom, and Ireland, with its NSAs specifically targeting the large unmet need for people suffering from depression, anxiety, and other mental health conditions. For those interested in learning more about the company's developments, additional information is available through the InvestorBrandNetwork, which provides access to the company's newsroom and comprehensive corporate communications solutions.
The news release was disseminated through TinyGems, a specialized communications platform within the Dynamic Brand Portfolio that focuses on innovative small-cap and mid-cap companies with significant growth potential. TinyGems offers extensive distribution capabilities including wire solutions via InvestorWire, article syndication to over 5,000 outlets, enhanced press release services, and social media distribution through IBN's network. Readers can access the full press release through the provided link to InvestorBrandNetwork, which serves as a comprehensive resource for investors and stakeholders following Helus Pharma's progress in the mental health pharmaceutical space.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Appoints Neuroscience Veteran to Advance Mental Health Treatments
